Demonstration Formulary
1 Gastro-intestinal system
fgsdfgsdfgs
01-05 Chronic bowel disorders
| Golimumab Simponi® |
|
Restricted
|
Specialist use only in line with NICE TA |
 NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) |
|
| Ustekinumab Stelara® |
|
Restricted
|
In line with NICE Hospital use only |
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
|
|
Links
- NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
- NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
- NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis